Compare Biogen Inc (BIIB) vs Icl Group Ltd (ICL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Icl Group Ltd — how do they compare? Biogen Inc trades at $195.54 (market cap $28.34B), while Icl Group Ltd trades at $5.03 (market cap $6.49B). The key difference: Biogen Inc is far larger — about 4.4× Icl Group Ltd's market cap, and Icl Group Ltd pays a 3.8% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | ICL | |
|---|---|---|
Market Cap | $28.34B | $6.49B |
Sector | Health | Basic Materials |
52-Week High | $216.63 | $7.03 |
52-Week Low | $122.68 | $4.80 |
Enterprise Value | $30.62B | $9.06B |
Dividend Yield | — | 3.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
ICL trades at $4.93, up 1.65% today, with a bearish technical signal and neutral oscillators. The company reported Q1 2026 EPS of $0.11, beating expectations, and maintains a dividend of $0.05. Revenue for 2025 was $7.15B with a net income margin of 3.52%, while valuation ratios like P/E of 23.48 and P/S of 0.86 suggest moderate pricing. Recent news highlights a $800M senior notes offering completed in June 2026.
Outlook is mixed: earnings beats and dividend yield offer support, but declining profit margins and bearish analyst consensus (100% hold) indicate caution. Key risks include raw material costs and forex headwinds, with institutional sentiment leaning neutral amid stable cash flows.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Icl Group Ltd
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →
